A Healthcare Technology Company

Shaping the future of noninvasive diagnosis with artificial intelligence.

Uniquely Positioned among Noninvasive technologies

A single blood draw Diagnostics powered by Artificial intelligence
using broadly available biomarkers that provides diagnostic accuracy equivalent to a biopsy.

Fibronostics patent technology

Patent Technology

CPT Code: 0166U

Fibronostics patent technology

De Novo 510K

(in Progress)

Fibronostics CE mark

CE mark

(Conformité Européenne)

Fibronostics patent technology

CLIA Certified

Fibronostics patent technology

Artificial Technology-Based Platform

LIVERFASt™ has now been granted a CPT Code.

The American Medical Association (AMA) and The Centers for Medicare & Medicaid Services (CMS) awarded LIVERFASt™ a CPT Code with the highest reimbursement fee in its category!

Complete Liver Diagnosis

LIVERFASt™ – from Early Stage to Late Stage
for NAFLD, NASH Cirrhosis & Hepatocellular Carcinoma.

Fibronostics Diagnosis


Noninvasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.

Fibronostics Screening


Risk stratification among large patient populations allows for better management leading to cost reductions.

Fibronostics Monitoring


Regular surveillance with easily repeatable noninvasive diagnostics enables optimized disease management.

Noninvasive solutions for diagnosis, screening and monitoring.